The current generation of biologic markers have three characteristics that differentiate them from previous ones. These include the ability to detect xenobiotics at concentrations at the cellular and molecular level, to detect earlier biologic changes presumptive of disease or disease risk, and to identify a detailed continuum of events between an exposure and resultant disease. If biomarkers are to enhance cancer epidemiology, they must be valid, reliable, and practical. When these characteristics have not been previously demonstrated, pilot studies should be conducted prior to the primary study. Interdisciplinary communication and collaboration is required so that useful markers are selected and that collection and handling, assay, and interpretation are appropriate. The status of many biomarkers is that they have been developed in the laboratory but lack validation for field use. Validation of a marker for use in a population requires attention to issues of background prevalence, sample size, natural history, persistence, variability, confounding factors, and predictive value. Additionally, practical features such as subject preparation, access to specimens, specimen storage aspects, and costs must be clarified. Ultimately, the use of biologic markers in epidemiologic studies will depend on how well the markers increase ability to reduce misclassification, provide for better interpretation of exposure-disease associations, and increase opportunities for prevention. Validation studies and general research using biomarkers also have clinical, ethical, and legal implications. These range from communicating uncertainty about the meaning of a marker to the kinds of societal response that result when groups or individuals are identified as having an "abnormal" marker frequency.
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Conceptual and Methodologic Issues
The scientific literature on biomarkers has been characterized more by attention to issues surrounding the development of assays than by the methodology for their use an exogenous exposure and a resultant disease. Biomarkers have been shown to be highly sensitive indicators. For example, it is possible to detect xenobiotic-DNA adduct binding at the level of 1 in 1015 adductednucleotides (1) . Markers have also been shown to detect cancer earlier than clinical diagnosis. For example, a combination of DNA hyperploidy and the M344 antibody allows detection of low-grade bladder cancers before they are morphologically apparent (2) . The generic model of a continuum of events between xenobiotic exposure and disease is now well known. It is illustrated in Figure 1 for exposure to ethylene oxide, a model that has been used in risk assessment (3) (4) (5) .
If biomarkers are to be useful in epidemiologic research, they must also be shown to be valid, reliable, and practical. These characteristics have been widely discussed (1, (6) (7) (8) (9) (15) have shown that slow acetylators develop more 4-aminobiphenyl-hemoglobin adducts than fast acetylators. Whether the acetylation phenotype is a risk factor for cancer has not been corroborated, despite widely cited references (16, 17) to a higher frequency of slow acetylators among bladder cancer cases. We plan studies in which incident bladder cancer cases and controls from exposed and nonexposed populations will be compared.
Until the validity, reliability, and practicality of a marker have been demonstrated, pilot studies are useful. Perera (1) and Everson (18) , among others, have demon-strated a strategy and approaches for such pilot studies: start with known high-dose groups such as chemotherapy patients, proceed to highly exposed occupational groups, then study occupational and environmental groups with lower exposure. The goal of these studies is or should be to determine the characteristics of markers that are prerequisites for their use in large population studies. These characteristics include a dose-response relationship, persistence, inter-and intra-person variation, correlation between markers, and correlation with clinical response. For example, Perera et al. (19) studied cancer patients treated with cisplatinum based chemotherapy and found post-treatment differences in a battery of biologic markers, including increased binding of hemoglobin and plasma protein to cisplatinum and increased levels of sister chromatid exchange.
A hallmark of the early studies utilizing biological markers is extensive interdisciplinary and often interinstitutional collaboration. It Figure 2 , which shows the extent of exposure history that can be represented by a biologic marker (20) . Factors that influence the dose of a xenobiotic must be considered. For example, Droz (21) (22) . Genotoxic agents are quite often specific in the effects they produce. For example, radiation induces primary chromosomal breaks and therefore produces kinetichore-negative micronuclei (22) , whereas a mixture of benzene metabolites induces an increase mainly in kinetichore-positive micronuclei (23) .
Use for Intervention
The best strategy for cancer intervention programs is to build them on a strong foundation of laboratory and epidemiologic research. Validated biologic markers that have been identified in epidemiologic studies as risk factors for a particular cancer may be the focus of primary or secondary prevention programs. For example, identification of slow acetylators among workers employed in industries where aromatic amines are used may provide a rationale for the frequency of screening for bladder cancer; however, if the relative risk for bladder cancer among slow acetylators is of the order of 1.5-2.0 and since approximately 50% of the population has this polymorphism, at least one-third of the population would be missed if a screening program were directed mainly at slow acetylators. An additional risk factor such as an exposure marker would reduce this oversight. Hence, by stratifying a work group on the basis of acetylation phenotype and arylamine-hemoglobin adduct levels, resources could be targeted to the workers at greatest risk (24, 25) . Prior to such use, however, the ethical and legal implications of distinguishing people on the basis of biologic markers need consideration.
Implications
The use of biologic markers imposes new clinical, ethical, and legal obligations upon researchers. These include scrutinizing the conditions involved in subject recruitment, specimen collection, and specimen access; reporting results; dealing with outliers; considering the effects of labeling subjects "abnormal"; and safeguarding privacy and confidentiality.
Subject Recruitment and Specimen Collection
The methods used for obtaining subjects or their specimens can raise ethical issues. The dangers include giving an implied or false sense of benefit when none is expected; misrepresenting the risk of harm in informed consent documents; or using any of various forms of coercion, ranging from making the subject fear incurring the displeasure of their physicians to the implicit or explicit indication that failure to participate will have implications for job security.
Attention must also be given to excluding potential subjects who may have a negative physiological reaction to the study procedure. For example, in a study of the debrisoquine phenotype using dextromethorphan, we had to address the concern of our Human Subjects Review Board about why we were not excluding subjects with cardiac arrhythmia or hypertension.
Access to Banked Specimens
A potentially controversial issue is the use of specimens for purposes for which they were not collected or by researchers not identified on the consent form. With the increasingly common practice of banking specimens and the fast pace of assay development and marker research, it is likely that there will be pressure to apply new assays to banked specimens without going back to the subjects for permission. This problem can be alleviated in part by using broad language on consent forms, although this may not be supported by institutional review boards. A second approach would be to have each new use for specimens assessed by a review panel, the members of which would serve as representatives of the subjects.
Communicating Results to Subjects
The whole issue of reporting results to study subjects is one that laboratory and field scientists have found difficult. Some argue that the findings are purely the results of research and are uninterpretable on an individual basis. Others take a more paternalistic attitude and decide that there is no good reason to convey the results because they have no implications for health.
When a researcher attempts to communicate results to study subjects, a number of issues must be considered. First, most current biomarker research has no clinical value, yet study subjects generally want to know if a study indicates if they are "all right." Second, many biomarker studies produce results of uncertain meaning to the investigator. How should this uncertainty be conveyed to research subjects? Currently, there is a paucity of data on ranges of normal levels for most biomarkers. Indeed, one of the objectives of contemporary research is to establish such ranges. Until that is done, it will be difficult to convey the full sense of what findings mean. One of the best ways to interpret results for subjects is to provide their individual results in comparison to those of the rest of the group being studied, although care must be taken with this approach since many factors influence a biomarker measurement. Other, more convoluted scenarios can be envisioned. For example, biomarkers that were purely research variables at the start of a study may be determined at some later time to indicate significant risk or clinical complications. What is our responsibility towards subjects in alerting them to these untoward findings?
Dealing with Subjects with Outlying Results and Labeling Subjects "Abnormal"
One reason for communicating the results of marker assays to subjects is that those with highly abnormal results can have appropriate medical follow-up. This is sensible in the context of medical tests but may not be generally feasible for research assays. Still, when there is some potential that a test is indicative of risk, a plan may need to be developed for dealing with subjects with outlying results. This might include repeating the assay, counseling, or recommending a diagnostic evaluation.
Persons with results in the tails of the statistical distribution may be labeled as "abnormal." This could lead to prejudicial responses from employers, insurers, lenders, and other social institutions that consider health-related matters in their deliberations.
Safeguarding Privacy and Confidentiality
Data collected in biologic marker studies, especially data that indicate risk, susceptibility, or potential early changes, may be used inappropriately. Thus, subjects of studies involving markers should be able to expect that their privacy will be maintained and their results kept confidential. This is especially true in relation to occupational opportunities and insurability. Employers may be able to prevent disease by excluding susceptible people from potentially harmful jobs and insurers may be able to save money by refusing to insure such people or insuring them at a higher rate. Using markers that have not been validated to make such decisions may put an unfair burden on study subjects (25) . There are many correlations (from cross-sectional studies) between genetic markers and disease, but very few markers have been validated with regard to predicting disease under exposure conditions (25, 26) . This issue initially arose in the context of genetic screening in the workplace. Since many cancer markers have a genetic component (i.e., they are phenotypic or genotypic expressions), the similarity between biomarker research and genetic screening may be quite close. Both require anticipatory vigilance against possible untoward or nefarious use of results. Even on the basis of validated markers, the advisability of discriminating against people with abnormal findings is questionable and should not be used in lieu of environmental control.
If biologic markers are to be useful in cancer epidemiology, attention must be paid not only to their use in studies but also to the societal impact of their use. This may require new forms of activity, such as marker registries, broader application of disability laws, and extensive followup testing. These activities typify extreme consequences. The most probable impacts on cancer epidemiology are the requirements to be open and communicative with subjects before, during, and after the study and to insure confidentiality of study findings. This approach should lead to continued productive research using biologic markers in cancer epidemiology.
